Quarterly report [Sections 13 or 15(d)]

Segment reporting - Segment profit or loss (Details)

v3.25.2
Segment reporting - Segment profit or loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment reporting            
Revenue $ 13,677   $ 128,231   $ 20,962 $ 133,909
Cost of goods sold (2,501)       (3,380) 0
Total operating expenses (43,965)   (59,531)   (96,983) (114,470)
(Loss)/profit from operations (30,288)   68,700   (76,021) 19,439
Interest income 233   1,376   1,143 2,721
Interest expense (962)   (526)   (2,843) (526)
Other income (expense), net 1,289   497   984 436
Income tax expense (612)   (526)   (1,187) (1,052)
Net (loss)/profit attributable to ordinary shareholders (30,340) $ (47,584) 69,521 $ (48,503) (77,924) 21,018
Research            
Segment reporting            
Total operating expenses 488   (3,830)   (1,620) (7,438)
CMC and Quality            
Segment reporting            
Total operating expenses (10,510)   (14,159)   (22,595) (28,933)
Biomarkers            
Segment reporting            
Total operating expenses (1,505)   (2,495)   (2,727) (5,286)
Development and Compliance            
Segment reporting            
Total operating expenses (9,552)   (12,611)   (20,102) (27,486)
Infrastructure management and facilities            
Segment reporting            
Total operating expenses (6,977)   (7,749)   (14,316) (15,828)
Commercial and Commercial planning            
Segment reporting            
Total operating expenses (3,946)   (2,561)   (8,344) (6,445)
Support and corporate functions            
Segment reporting            
Total operating expenses (10,172)   (9,139)   (22,811) (21,073)
Other segment expenses            
Segment reporting            
Total operating expenses $ 710   $ (6,987)   $ (1,088) $ (1,981)